Skip to content
← The Index board

Promising · 6/10

SS-31 (Elamipretide)

Evidence C · mixed evidence ▲ 39.6% momentum 🥇 First scout open
6/ 10

SS-31 (elamipretide) is a mitochondria-targeting tetrapeptide that binds cardiolipin. Karaa 2023 found no broad PMM benefit in MMPOWER-3, while FDA granted accelerated Forzinity approval for Barth syndrome in patients weighing at least 30 kg. Read the full breakdown →

The prediction game

Where does SS-31 (Elamipretide) go in 12 months?

Lock a call and say how sure you are. Right and confident earns the most; a leaderboard spot is the prize. No money, no stakes.

The Crowd’s Call

Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.

Your 12-month call on SS-31 (Elamipretide)

New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.

Be the first scout on record for SS-31 (Elamipretide). Permanent credit on this page, plus points when your call resolves.

One call per intervention. It locks the moment you submit (no edits, no cancels) and resolves in 12 months. See the scout leaderboard →

Weigh In

Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.

Tried it in real life?

Which ring does it deserve?

Same as above — one verification covers all your entries here.

Related reading

Ring Promising Momentum 39.6% Updated Jul 20, 2026 How the Index ranks →

Verdict by Nick Urban, host of the High Performance Longevity podcast.

For education only, not medical advice. Supplements, peptides, and protocols can interact with medications and conditions. Talk to a qualified clinician before starting anything here.